Bank of America Initiates Buy on Ligand Pharmaceuticals with $244 Target
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 11 2026
0mins
Should l Buy LGND?
Source: seekingalpha
- Coverage Initiation: Bank of America has initiated coverage on Ligand Pharmaceuticals (LGND) with a Buy rating and a $244 price target, emphasizing its high-margin yet lower-risk business model, which is expected to attract increased investor interest.
- Unique Business Model: Analyst Jason Zemansky noted that Ligand generates diversified, high-margin returns by providing capital and technology to drug and medical device developers, showcasing its unique business model that enhances market competitiveness.
- Investment Team Strength: Zemansky highlighted that Ligand's investment team is one of its greatest assets, with decades of experience and strong industry relationships, demonstrating a solid execution record that adds credibility to the company's thesis.
- Sustained Growth Potential: Despite outperforming its biotech peers over the past 12 months, Ligand's stock is poised for further gains, as increased investor confidence in meeting its annual and long-term growth targets is likely to drive greater market engagement.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LGND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LGND
Wall Street analysts forecast LGND stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 195.480
Low
220.00
Averages
237.20
High
270.00
Current: 195.480
Low
220.00
Averages
237.20
High
270.00
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ligand Pharmaceuticals Executive Exercises Stock Options
- Stock Option Exercise: Andrew Reardon, Chief Legal Officer of Ligand Pharmaceuticals, exercised 5,000 stock options on March 4, 2026, at an exercise price of $52.27, and sold them at a market price of $206.35, resulting in a transaction value of approximately $1.03 million, reflecting the company's strong stock performance.
- Change in Holdings: This transaction reduced Reardon's direct holdings by 11.94%, from 48,869 shares to 36,869 shares; however, he still retains 54,444 employee stock options, ensuring continued exposure to the company's future growth.
- Market Performance Context: Prior to this transaction, Ligand's stock had appreciated by approximately 81% over the past year, providing Reardon with a favorable window to act, indicating the company's robust growth potential in the biopharmaceutical sector.
- Pre-Planned Transaction: The transaction was pre-scheduled under a 10b5-1 plan adopted in November 2025, indicating that Reardon's decision was based on confidence in the company's long-term performance rather than short-term market fluctuations.
See More
Ligand Pharmaceuticals Executive Sells Stock Options for $1.03 Million
- Executive Stock Transaction: Ligand Pharmaceuticals' Chief Legal Officer Andrew Reardon exercised 5,000 stock options and immediately sold them for approximately $1.03 million, reflecting his confidence in the company's future prospects.
- Transaction Scale Analysis: The sale of 5,000 shares is significantly larger than Reardon's recent average sale of 750 shares, indicating a notable change in his holding pattern, with direct ownership declining by 11.94%.
- Market Performance Impact: Conducted in a strong market environment with Ligand shares priced around $206.35, this transaction demonstrates Reardon's strategic monetization of stock appreciation, as evidenced by an 81.3% total return over the past year.
- Long-term Holding Strategy: Despite the reduction in direct holdings, Reardon retains 54,444 employee stock options, ensuring continued equity participation and exposure to Ligand's growth story through future option exercises.
See More
Ligand Pharmaceuticals CFO Sells $688,000 in Stock
- Executive Stock Sale: On March 11, 2026, Ligand Pharmaceuticals CFO Octavio Espinoza sold 3,057 shares of common stock for approximately $688,000, indicating active management participation in the market.
- Transaction Context: The sale included 2,405 shares acquired through the exercise of vested stock options, with the entire block sold immediately, reflecting Espinoza's strategic financial planning.
- Equity Exposure Change: This sale represented 12.70% of Espinoza's direct common stock ownership, leaving him with 21,010 shares valued at approximately $4.65 million, demonstrating his continued confidence in the company's future.
- Company Performance Growth: Ligand reported total revenue of $268.1 million in 2025, a 48% increase from $167.1 million the previous year, with forecasts of up to $285 million in revenue for 2026, highlighting strong growth potential in the biopharmaceutical sector.
See More
BofA Initiates Coverage on Ligand Pharmaceuticals with Buy Rating
- Unique Business Model: Ligand Pharmaceuticals operates as a biopharmaceutical royalty aggregator, providing financing and licensing to biopharma developers, showcasing strong growth potential with ambitious revenue and earnings targets.
- Strong Financial Performance: The company reported fourth-quarter adjusted earnings of $2.02 per share, exceeding the consensus of $1.56, with sales reaching $59.7 million, surpassing Wall Street's estimate of $55.6 million, indicating robust profitability.
- Future Growth Potential: With 12 major commercial-stage assets, Ligand is well-positioned to support its profit and loss, while its portfolio of over 100 programs offers additional revenue opportunities, demonstrating strong market competitiveness.
- Attractive Valuation: BofA initiated coverage with a Buy rating and a price target of $244, highlighting Ligand's higher margins and lower infrastructure needs compared to traditional biopharma firms, suggesting a positive outlook for future growth.
See More
LIGAND PHARMACEUTICALS INC: BOFA GLOBAL RESEARCH STARTS COVERAGE WITH A BUY RATING AND A TARGET PRICE OF $244
Company Overview: LIGAND PHARMACEUTICALS is involved in global research initiatives, particularly in the pharmaceutical sector.
Market Activity: The company has a buy rating with a price objective set at $244, indicating positive investor sentiment.
See More
Bank of America Initiates Buy on Ligand Pharmaceuticals with $244 Target
- Coverage Initiation: Bank of America has initiated coverage on Ligand Pharmaceuticals (LGND) with a Buy rating and a $244 price target, emphasizing its high-margin yet lower-risk business model, which is expected to attract increased investor interest.
- Unique Business Model: Analyst Jason Zemansky noted that Ligand generates diversified, high-margin returns by providing capital and technology to drug and medical device developers, showcasing its unique business model that enhances market competitiveness.
- Investment Team Strength: Zemansky highlighted that Ligand's investment team is one of its greatest assets, with decades of experience and strong industry relationships, demonstrating a solid execution record that adds credibility to the company's thesis.
- Sustained Growth Potential: Despite outperforming its biotech peers over the past 12 months, Ligand's stock is poised for further gains, as increased investor confidence in meeting its annual and long-term growth targets is likely to drive greater market engagement.
See More
Ligand Pharmaceuticals Executive Exercises Stock Options
- Stock Option Exercise: Andrew Reardon, Chief Legal Officer of Ligand Pharmaceuticals, exercised 5,000 stock options on March 4, 2026, at an exercise price of $52.27, and sold them at a market price of $206.35, resulting in a transaction value of approximately $1.03 million, reflecting the company's strong stock performance.
- Change in Holdings: This transaction reduced Reardon's direct holdings by 11.94%, from 48,869 shares to 36,869 shares; however, he still retains 54,444 employee stock options, ensuring continued exposure to the company's future growth.
- Market Performance Context: Prior to this transaction, Ligand's stock had appreciated by approximately 81% over the past year, providing Reardon with a favorable window to act, indicating the company's robust growth potential in the biopharmaceutical sector.
- Pre-Planned Transaction: The transaction was pre-scheduled under a 10b5-1 plan adopted in November 2025, indicating that Reardon's decision was based on confidence in the company's long-term performance rather than short-term market fluctuations.
See More
Ligand Pharmaceuticals Executive Sells Stock Options for $1.03 Million
- Executive Stock Transaction: Ligand Pharmaceuticals' Chief Legal Officer Andrew Reardon exercised 5,000 stock options and immediately sold them for approximately $1.03 million, reflecting his confidence in the company's future prospects.
- Transaction Scale Analysis: The sale of 5,000 shares is significantly larger than Reardon's recent average sale of 750 shares, indicating a notable change in his holding pattern, with direct ownership declining by 11.94%.
- Market Performance Impact: Conducted in a strong market environment with Ligand shares priced around $206.35, this transaction demonstrates Reardon's strategic monetization of stock appreciation, as evidenced by an 81.3% total return over the past year.
- Long-term Holding Strategy: Despite the reduction in direct holdings, Reardon retains 54,444 employee stock options, ensuring continued equity participation and exposure to Ligand's growth story through future option exercises.
See More
Ligand Pharmaceuticals CFO Sells $688,000 in Stock
- Executive Stock Sale: On March 11, 2026, Ligand Pharmaceuticals CFO Octavio Espinoza sold 3,057 shares of common stock for approximately $688,000, indicating active management participation in the market.
- Transaction Context: The sale included 2,405 shares acquired through the exercise of vested stock options, with the entire block sold immediately, reflecting Espinoza's strategic financial planning.
- Equity Exposure Change: This sale represented 12.70% of Espinoza's direct common stock ownership, leaving him with 21,010 shares valued at approximately $4.65 million, demonstrating his continued confidence in the company's future.
- Company Performance Growth: Ligand reported total revenue of $268.1 million in 2025, a 48% increase from $167.1 million the previous year, with forecasts of up to $285 million in revenue for 2026, highlighting strong growth potential in the biopharmaceutical sector.
See More
BofA Initiates Coverage on Ligand Pharmaceuticals with Buy Rating
- Unique Business Model: Ligand Pharmaceuticals operates as a biopharmaceutical royalty aggregator, providing financing and licensing to biopharma developers, showcasing strong growth potential with ambitious revenue and earnings targets.
- Strong Financial Performance: The company reported fourth-quarter adjusted earnings of $2.02 per share, exceeding the consensus of $1.56, with sales reaching $59.7 million, surpassing Wall Street's estimate of $55.6 million, indicating robust profitability.
- Future Growth Potential: With 12 major commercial-stage assets, Ligand is well-positioned to support its profit and loss, while its portfolio of over 100 programs offers additional revenue opportunities, demonstrating strong market competitiveness.
- Attractive Valuation: BofA initiated coverage with a Buy rating and a price target of $244, highlighting Ligand's higher margins and lower infrastructure needs compared to traditional biopharma firms, suggesting a positive outlook for future growth.
See More
LIGAND PHARMACEUTICALS INC: BOFA GLOBAL RESEARCH STARTS COVERAGE WITH A BUY RATING AND A TARGET PRICE OF $244
Company Overview: LIGAND PHARMACEUTICALS is involved in global research initiatives, particularly in the pharmaceutical sector.
Market Activity: The company has a buy rating with a price objective set at $244, indicating positive investor sentiment.
See More
Bank of America Initiates Buy on Ligand Pharmaceuticals with $244 Target
- Coverage Initiation: Bank of America has initiated coverage on Ligand Pharmaceuticals (LGND) with a Buy rating and a $244 price target, emphasizing its high-margin yet lower-risk business model, which is expected to attract increased investor interest.
- Unique Business Model: Analyst Jason Zemansky noted that Ligand generates diversified, high-margin returns by providing capital and technology to drug and medical device developers, showcasing its unique business model that enhances market competitiveness.
- Investment Team Strength: Zemansky highlighted that Ligand's investment team is one of its greatest assets, with decades of experience and strong industry relationships, demonstrating a solid execution record that adds credibility to the company's thesis.
- Sustained Growth Potential: Despite outperforming its biotech peers over the past 12 months, Ligand's stock is poised for further gains, as increased investor confidence in meeting its annual and long-term growth targets is likely to drive greater market engagement.
See More
